JP7868811B2 - イヌ細胞傷害性tリンパ球関連タンパク質4(ctla-4)に対するイヌモノクローナル抗体 - Google Patents

イヌ細胞傷害性tリンパ球関連タンパク質4(ctla-4)に対するイヌモノクローナル抗体

Info

Publication number
JP7868811B2
JP7868811B2 JP2023565183A JP2023565183A JP7868811B2 JP 7868811 B2 JP7868811 B2 JP 7868811B2 JP 2023565183 A JP2023565183 A JP 2023565183A JP 2023565183 A JP2023565183 A JP 2023565183A JP 7868811 B2 JP7868811 B2 JP 7868811B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023565183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516621A (ja
JP2024516621A5 (cg-RX-API-DMAC7.html
Inventor
ニコラ ジェイ. メイソン
ドナルド エル. シーゲル
ニコラス チェスター
Original Assignee
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
ベチジェニックス,インク.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア, ベチジェニックス,インク. filed Critical ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア
Publication of JP2024516621A publication Critical patent/JP2024516621A/ja
Publication of JP2024516621A5 publication Critical patent/JP2024516621A5/ja
Application granted granted Critical
Publication of JP7868811B2 publication Critical patent/JP7868811B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023565183A 2021-04-21 2022-04-20 イヌ細胞傷害性tリンパ球関連タンパク質4(ctla-4)に対するイヌモノクローナル抗体 Active JP7868811B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163177692P 2021-04-21 2021-04-21
US63/177,692 2021-04-21
PCT/US2022/025614 WO2022226102A1 (en) 2021-04-21 2022-04-20 Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4)

Publications (3)

Publication Number Publication Date
JP2024516621A JP2024516621A (ja) 2024-04-16
JP2024516621A5 JP2024516621A5 (cg-RX-API-DMAC7.html) 2025-04-08
JP7868811B2 true JP7868811B2 (ja) 2026-06-02

Family

ID=83723402

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565183A Active JP7868811B2 (ja) 2021-04-21 2022-04-20 イヌ細胞傷害性tリンパ球関連タンパク質4(ctla-4)に対するイヌモノクローナル抗体

Country Status (5)

Country Link
US (2) US12110331B2 (cg-RX-API-DMAC7.html)
EP (1) EP4326324A4 (cg-RX-API-DMAC7.html)
JP (1) JP7868811B2 (cg-RX-API-DMAC7.html)
CA (1) CA3216131A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022226102A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4326324A4 (en) * 2021-04-21 2026-03-25 Univ Pennsylvania Canine Monoclonal Antibodies Against Canine Cytotoxic T Lymphocyte-Associated Protein 4 (CTLA-4)
CN120265660A (zh) * 2023-04-28 2025-07-04 宾夕法尼亚大学董事会 新型cd19靶向多肽和cd19定向免疫疗法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040181039A1 (en) 2001-12-21 2004-09-16 Krah Eugene Regis Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
WO2021009187A1 (en) 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies against canine ctla-4

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA314534A (en) * 1931-08-25 The United States Gypsum Company Roof or floor
WO2009126730A2 (en) * 2008-04-09 2009-10-15 The Trustees Of The University Of Pennsylvania Canine single chain fragment variable antibody libraries and uses thereof
EP4326324A4 (en) * 2021-04-21 2026-03-25 Univ Pennsylvania Canine Monoclonal Antibodies Against Canine Cytotoxic T Lymphocyte-Associated Protein 4 (CTLA-4)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040181039A1 (en) 2001-12-21 2004-09-16 Krah Eugene Regis Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
WO2021009187A1 (en) 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies against canine ctla-4

Also Published As

Publication number Publication date
US20250171541A1 (en) 2025-05-29
JP2024516621A (ja) 2024-04-16
EP4326324A4 (en) 2026-03-25
CA3216131A1 (en) 2022-10-27
US20240109967A1 (en) 2024-04-04
EP4326324A1 (en) 2024-02-28
WO2022226102A1 (en) 2022-10-27
US12110331B2 (en) 2024-10-08

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20260312

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260406

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260512

R150 Certificate of patent or registration of utility model

Ref document number: 7868811

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150